Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Biometrics
|
November 9, 2011
Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework
Yue Wang, Robin Mogg, Jared Lunceford
BMJ Open
|
October 16, 2012
Level of phosphohistone H3 among various types of human cancers
Amy Sun, Wei Zhou, Jared Lunceford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2017
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
Toshihiko Doi, Sarina A Piha-Paul, Shadia I Jalal, et al.
Journal for Immunotherapy of Cancer
|
February 1, 2022
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
Razvan Cristescu, Deepti Aurora-Garg, Andrew Albright, et al.
Gynecologic Oncology
|
June 25, 2026
Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancer
Alexander Yarunin, Ping Qiu, Xiaodun Li, et al.
The Lancet. Oncology
|
January 14, 2017
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
Elizabeth R Plimack, Joaquim Bellmunt, Shilpa Gupta, et al.
Journal of the American Society of Nephrology : JASN
|
January 18, 2008
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy
Hans-Henrik Parving, Dick de Zeeuw, Mark E Cooper, et al.
The Lancet. Oncology
|
June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.
Archives of Pathology & Laboratory Medicine
|
July 21, 2018
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara, Nancy Zhang, Ellie Corigliano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2017
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H Yearley, Christopher Gibson, Ni Yu, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Biometrics
|
November 9, 2011
Evaluating correlation-based metric for surrogate marker qualification within a causal correlation framework
Yue Wang, Robin Mogg, Jared Lunceford
BMJ Open
|
October 16, 2012
Level of phosphohistone H3 among various types of human cancers
Amy Sun, Wei Zhou, Jared Lunceford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 9, 2017
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
Toshihiko Doi, Sarina A Piha-Paul, Shadia I Jalal, et al.
Journal for Immunotherapy of Cancer
|
February 1, 2022
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
Razvan Cristescu, Deepti Aurora-Garg, Andrew Albright, et al.
Gynecologic Oncology
|
June 25, 2026
Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancer
Alexander Yarunin, Ping Qiu, Xiaodun Li, et al.
The Lancet. Oncology
|
January 14, 2017
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
Elizabeth R Plimack, Joaquim Bellmunt, Shilpa Gupta, et al.
Journal of the American Society of Nephrology : JASN
|
January 18, 2008
ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy
Hans-Henrik Parving, Dick de Zeeuw, Mark E Cooper, et al.
The Lancet. Oncology
|
June 2, 2016
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y Seiwert, Barbara Burtness, Ranee Mehra, et al.
Archives of Pathology & Laboratory Medicine
|
July 21, 2018
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara, Nancy Zhang, Ellie Corigliano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 17, 2017
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H Yearley, Christopher Gibson, Ni Yu, et al.
Page
of 3